The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

Szczyrek, Michał; Bitkowska, Paulina; Jutrzenka, Marta; Milanowski, Janusz

doi:10.3390/jpm12081227

Cited by 8 publications

(3 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have found that miR-375 has prognostic and predictive values in LCNEC. Increased miR-375 expression has been associated with poor prognosis in LCNEC, with a median survival of 8-12 months [28][29][30]. These studies assessed the predictive value of mir375 as a biomarker for chemotherapy-treated patients.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

Evangelou,

Trontzas,

Gkiozos

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Large-cell neuroendocrine carcinoma presents significant treatment challenges owing to its rarity and limited therapeutic options. The LANCE study was designed to explore the survival benefits of incorporating atezolizumab in chemotherapy for metastatic LCNEC. Methods: In this non-randomized study, patients with metastatic LCNEC were treated with ei-ther standard chemotherapy plus atezolizumab or standard chemotherapy alone. The primary outcomes measured were progression-free survival (PFS) and overall survival (OS), with an ex-ploratory analysis of miR375 in plasma as a potential biomarker. Results: Of the 22 screened patients, 17 met the inclusion criteria and were stratified into the atezolizumab and chemotherapy (n=10) or chemotherapy alone(n=7) groups. After a median follow-up of 23.3 months, the 12-month survival rate for the atezolizumab group was 57.1% (95% CI: 32.6%-100%) and 45.7% at 24 months (95% CI: 22.4%-93.2%). In contrast, the chemotherapy group had a 14.3% survival rate at both 12 and 24 months (95% CI: 2.33%-87.7%). The log-rank test for survival showed a statistically significant difference in the atezolizumab-treated group (chi-squared = 4, df = 1, p = 0.04). A non-significant correlation was found between disease pro-gression and elevated levels of miR375. Conclusions: This pilot study suggests that atezolizumab combined with chemotherapy may be effective in treating metastatic LCNEC. The non-significant correlation between plasma miR375 levels and disease progression suggests its biomarker potential, warranting further validation research.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

Evangelou,

Trontzas,

Gkiozos

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…miRNAs modulate several intracellular signaling pathways and induce many effects. These molecules can be classified according to their effects on tumor-suppressive miRNAs and oncogenic miRNAs (oncomirs) [ 12 , 15 ].…”

Section: Regulation Of Mirnas In Key Signaling Pathways Involved In N...mentioning

confidence: 99%

“…Although studies are available regarding the role of several miRNAs in lung cancer tissue in the prognosis of patients with NSCLC, these have mainly evaluated cell lines in in vitro models, and few data are currently available on human lung cancer tissue [ 15 ].…”

Section: Role Of Mirnas As Prognostic Factors In Patients With Nsclcmentioning

confidence: 99%

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment

Nucera,

Ruggeri,

Spagnolo

et al. 2024

IJMS

View full text Add to dashboard Cite

Lung cancer (LC) is one of the most prevalent cancers in both men and women and today is still characterized by high mortality and lethality. Several biomarkers have been identified for evaluating the prognosis of non-small cell lung cancer (NSCLC) patients and selecting the most effective therapeutic strategy for these patients. The introduction of innovative targeted therapies and immunotherapy with immune checkpoint inhibitors (ICIs) for the treatment of NSCLC both in advanced stages and, more recently, also in early stages, has revolutionized and significantly improved the therapeutic scenario for these patients. Promising evidence has also been shown by analyzing both micro-RNAs (miRNAs) and the lung/gut microbiota. MiRNAs belong to the large family of non-coding RNAs and play a role in the modulation of several key mechanisms in cells such as proliferation, differentiation, inflammation, and apoptosis. On the other hand, the microbiota (a group of several microorganisms found in human orgasms such as the gut and lungs and mainly composed by bacteria) plays a key role in the modulation of inflammation and, in particular, in the immune response. Some data have shown that the microbiota and the related microbiome can modulate miRNAs expression and vice versa by regulating several intracellular signaling pathways that are known to play a role in the pathogenesis of lung cancer. This evidence suggests that this axis is key to predicting the prognosis and effectiveness of ICIs in NSCLC treatment and could represent a new target in the treatment of NSCLC. In this review, we highlight the most recent evidence and data regarding the role of both miRNAs and the lung/gut microbiome in the prediction of prognosis and response to ICI treatment, focusing on the link between miRNAs and the microbiome. A new potential interaction based on the underlying modulated intracellular signaling pathways is also shown.

show abstract

Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer

Kazemi Shariat Panahi,

Dehhaghi,

Guillemin

et al. 2023

Cancer Metastasis Rev

View full text Add to dashboard Cite

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

Cited by 8 publications

References 111 publications

Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

Effectiveness of Atezolizumab in Metastatic Large Cell Neuroendocrine Carcinoma of the Lung and the Predictive Value of miR-375. The LANCE Trial, a Pilot Study

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment

Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer

Contact Info

Product

Resources

About